Literature DB >> 3625464

Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma.

J G Toma, H M Amerongen, S C Hennes, M G O'Brien, W A McBlain, G R Buzzell.   

Abstract

Conventional antiandrogen therapy for prostatic cancer generally results in the death of androgen-dependent cells, resulting in shrinkage of the tumor, followed by regrowth of the tumor as androgen-insensitive cells take over. Because of reported antigonadotropic and antineoplastic effects of the pineal hormone melatonin (MEL), we hypothesized that this indole might provide an effective therapy for prostate cancer, as it would be effective against both populations of tumor cells. We used three sublines of the Dunning R3327 rat prostatic adenocarcinoma to determine whether MEL could suppress the growth of these tumors and, if so, by what mechanisms this occurs. In one experiments, we compared the growth of a well-differentiated slow-growing Dunning tumor in rats given MEL combined with the potentiating procedure olfactory bulbectomy (BULBX), with that in rats pinealectomized (PINX) or untreated. Tumor growth in BULBX-MEL rats was significantly suppressed over that in the other two groups, as were the weights of the gonads and accessory sex glands. Tumor morphology, DNA concentration, and androgen receptor concentration and distribution were identical in untreated controls and in BULBX-MEL rats, suggesting that the treatment affected all populations of tumor cells equally. With another strain of well-differentiated slow-growing Dunning tumor, we examined the effects of MEL in rats with and without BULBX. Reproductive parameters were not suppressed in BULBX-MEL rats and, while there was a trend toward slower tumor growth in this group, this was not significant. Intact rats given MEL grew larger tumors than did control rats but, again, differences were not significant. In a third experiment, we examined a fast-growing androgen-insensitive anaplastic Dunning tumor. PINX was without effect on this tumor, but BULBX-MEL resulted in a significant suppression of one of the constants in the logistic equation fitted to the growth curves. This indicates that there were some direct antitumor effects of BULBX-MEL on this tumor strain. We conclude that MEL suppresses growth of some Dunning tumor strains.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625464     DOI: 10.1111/j.1600-079x.1987.tb00870.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  8 in total

Review 1.  Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Katja Fall; Jennifer R Rider; Steven W Lockley; Eva Schernhammer; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

Review 2.  WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Authors:  Zsofia Kiss; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2016-09-22       Impact factor: 5.678

3.  Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor.

Authors:  G R Buzzell
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

4.  Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.

Authors:  Latifa A Bazzi; Lara G Sigurdardottir; Sigurdur Sigurdsson; Unnur Valdimarsdottir; Johanna Torfadottir; Thor Aspelund; Charles A Czeisler; Steven W Lockley; Eirikur Jonsson; Lenore Launer; Tamara Harris; Vilmundur Gudnason; Lorelei A Mucci; Sarah C Markt
Journal:  Prostate       Date:  2021-04-16       Impact factor: 4.012

5.  Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.

Authors:  Fangyi Gu; Han Zhang; Paula L Hyland; Sonja Berndt; Susan M Gapstur; William Wheeler; The Ellipse Consortium; Christopher I Amos; Stephane Bezieau; Heike Bickeböller; Hermann Brenner; Paul Brennan; Jenny Chang-Claude; David V Conti; Jennifer Anne Doherty; Stephen B Gruber; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; Richard S Houlston; Rayjean J Hung; Mark A Jenkins; Peter Kraft; Kate Lawrenson; James McKay; Sarah Markt; Lorelei Mucci; Catherine M Phelan; Conghui Qu; Angela Risch; Mary Anne Rossing; H-Erich Wichmann; Jianxin Shi; Eva Schernhammer; Kai Yu; Maria Teresa Landi; Neil E Caporaso
Journal:  Int J Cancer       Date:  2017-07-29       Impact factor: 7.316

Review 6.  Melatonin and Cancer: A Polyhedral Network Where the Source Matters.

Authors:  Maria-Angeles Bonmati-Carrion; Antonia Tomas-Loba
Journal:  Antioxidants (Basel)       Date:  2021-02-01

Review 7.  Potential Therapeutic Effects of Melatonin Mediate via miRNAs in Cancer.

Authors:  Pirouz Pourmohammad; Nazila Fathi Maroufi; Mohsen Rashidi; Vahid Vahedian; Farhad Pouremamali; Yousef Faridvand; Mahsa Ghaffari-Novin; Alireza Isazadeh; Saba Hajazimian; Hamid Reza Nejabati; Mohammad Nouri
Journal:  Biochem Genet       Date:  2021-06-28       Impact factor: 1.890

Review 8.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.